Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - Implications for systemic control.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

[Relationship between doses to anatomical structures and erectile dysfunction after radiotherapy for prostate cancer: A systematic review].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

Silo Experience.

Hall's journal of health·2022
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Oct 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Ultrahypofractionated Radiotherapy for Localised Prostate Cancer: How Far Can We Go?

M T Corkum1, V Achard2, G Morton3

  • 1Division of Radiation Oncology, Department of Radiology, The Ottawa Hospital, Ottawa, Ontario, Canada.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 28, 2021
PubMed
Summary
This summary is machine-generated.

Radiotherapy for localized prostate cancer can be safely delivered in fewer than five fractions. High dose rate brachytherapy and stereotactic body radiotherapy show promising results for hypofractionated treatment.

Keywords:
Dose fractionationhigh dose rate brachytherapyprostate cancerstereotactic body radiotherapy

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K

Related Experiment Videos

Last Updated: Oct 8, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.0K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Hypofractionated radiotherapy is a standard for localized prostate cancer.
  • Ultrahypofractionated radiotherapy (5-7 fractions) is increasingly adopted.
  • The feasibility of fewer than five fractions requires investigation.

Purpose of the Study:

  • To review evidence on the safety and efficacy of delivering radiotherapy in fewer than five fractions for localized prostate cancer.
  • To explore the potential of ultra-hypofractionated regimens.

Main Methods:

  • Review of existing literature on prostate cancer radiotherapy.
  • Analysis of data from high dose rate brachytherapy and stereotactic body radiotherapy studies.
  • Examination of single-fraction high dose rate brachytherapy outcomes.

Main Results:

  • Evidence supports the safe and effective delivery of radiotherapy in fewer than five fractions.
  • High dose rate brachytherapy and stereotactic body radiotherapy are viable options.
  • Single-fraction high dose rate brachytherapy provides valuable insights.

Conclusions:

  • Fewer than five fractions of radiotherapy are feasible for localized prostate cancer.
  • Ultra-hypofractionated approaches, including brachytherapy and SBRT, are effective.
  • Further research can optimize ultra-hypofractionated treatment protocols.